Ocular Therapeutix (OCUL) Current Assets (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Current Assets of $644.4 million for Q2 2026, up 48.7% year-over-year from $433.4 million in Q2 2025, and down 8.72% on a QoQ basis from $706.0 million in Q1 2026.
Ocular Therapeutix (OCUL) Current Assets (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Current Assets for 14 years, with the latest figure at $644.4 million in Q2 2026.
- Current Assets for Q2 2026 came in at $644.4 million, up 48.7% year-over-year; the trailing twelve-month figure through Jun 2026 was $644.4 million (up 48.7% YoY), and the FY2025 annual result was $782.1 million, up 77.36% from the prior year.
- Current Assets slipped to $644.4 million in Q2 2026, from $706.0 million in the prior quarter.
- Over five years, Current Assets peaked at $782.1 million in Q4 2025 and troughed at $100.7 million in Q2 2023.
- A 5-year average of $359.1 million and a median of $387.3 million in 2025 frame the typical range for Current Assets.
- The widest annual swing landed in 2023, when Current Assets sank 38.64%; it then jumped 395.06% in 2024.
- A 5-year view of Current Assets shows it stood at $129.6 million in 2022, then jumped by 79.16% to $232.2 million in 2023, then surged by 89.89% to $441.0 million in 2024, then jumped by 77.36% to $782.1 million in 2025, then dropped by 17.61% to $644.4 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $644.4 million in Q2 2026, $706.0 million in Q1 2026, and $782.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 644.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 644.43 Mn |
| Mar 31, 2026 | 706.00 Mn |
| Dec 31, 2025 | 782.13 Mn |
| Sep 30, 2025 | 386.98 Mn |
| Jun 30, 2025 | 433.38 Mn |
| Mar 31, 2025 | 387.69 Mn |
| Dec 31, 2024 | 440.99 Mn |
| Sep 30, 2024 | 473.01 Mn |
| Jun 30, 2024 | 498.59 Mn |
| Mar 31, 2024 | 519.82 Mn |
| Dec 31, 2023 | 232.24 Mn |
| Sep 30, 2023 | 141.26 Mn |
| Jun 30, 2023 | 100.71 Mn |
| Mar 31, 2023 | 107.16 Mn |
| Dec 31, 2022 | 129.63 Mn |
| Sep 30, 2022 | 145.62 Mn |
| Jun 30, 2022 | 160.32 Mn |
| Mar 31, 2022 | 174.65 Mn |
| Dec 31, 2021 | 191.30 Mn |
| Sep 30, 2021 | 203.93 Mn |